Triptolide reduces cyst formation in a neonatal to adult transition Pkd1 model of ADPKD

Stephanie J. Leuenroth¹, Natasha Bencivenga¹, Halima Chahboune², Fahmeed Hyder²,³ and Craig M. Crews¹,⁴,⁵

¹Department of Molecular, Cellular, and Developmental Biology, Yale University, New Haven, CT 06511, USA, ²Department of Diagnostic Radiology, Yale University, New Haven, CT 06511, USA, ³Department of Biomedical Engineering, Yale University, New Haven, CT 06511, USA, ⁴Department of Pharmacology, Yale University, New Haven, CT 06511, USA and ⁵Department of Chemistry, Yale University, New Haven, CT 06511, USA

Correspondence and offprint requests to: Craig M. Crews; E-mail: craig.crews@yale.edu

Abstract

Background. Autosomal dominant polycystic kidney disease (ADPKD), a major cause of end-stage renal failure, results from genetic mutation of either polycystin-1 (Pkd1) or polycystin-2 (Pkd2). In order to develop novel therapies to treat the advancement of disease progression, numerous rodent models of different genetic backgrounds are available to study cyst development.

Methods. Here, a Pkd1-floxed inducible mouse model using the interferon responsive Mx1Cre-recombinase was utilized to test the effect of the small molecule triptolide. Relative to other Pkd1 inactivation models, cyst progression in this neonatal to adult transition model is attenuated. Following the characterization of inducible cyst formation in these mice, the development of kidney cysts from triptolide or vehicle-treated animals was analysed.

Results. Although Pkd1 deletion on postnatal Days P10 and P12 resulted in numerous cysts by P35, daily injections with triptolide beginning on Day P16 significantly reduced the total number of cysts per kidney, with a pronounced effect on the number of microcysts and the overall cystic burden. Additionally, renal function as assessed by blood urea nitrogen levels was also improved in triptolide-treated mice at both the P22 and P35 time points. As the Pkd1flox/flox; Mx1Cre model has not been previously used for drug development studies, the feasibility of a 6-month adult Pkd1 inactivation study was also tested. While kidney cyst formation was minimal and focal in nature, livers of these Pkd1-deficient mice were severely cystic, enlarged and pale.

Conclusions. These results suggest that the Pkd1flox/flox; Mx1Cre model of ADPKD is amenable to short-term kidney cyst formation drug studies; however, it may be problematic for long-term therapeutic research where widespread liver cysts and fibrosis could compromise drug metabolism.

Keywords: ADPKD; polycystic; triptolide

Introduction

Autosomal dominant polycystic kidney disease (ADPKD) is characterized by the progressive formation and expansion of fluid-filled kidney cysts ultimately leading to a decline in kidney function and end-stage renal disease (ESRD). A defect in the gene product of either Pkd1 (85% of all ADPKD cases) or Pkd2 (15% of cases) is thought to result in a loss of calcium signalling in kidney epithelial cells and a reversion to the proliferative phenotype [1,2]. There are numerous murine models of ADPKD available with varying genetic backgrounds, including several with Pkd1 deficiencies [3–9]. Those models utilizing inducible Pkd1 inactivation allow for the study of rapid kidney cyst formation in neonates as well as a delayed disease progression in adult mice [4,6,10], as
previous findings demonstrate a difference in the timing of cystogenesis due to Pkd1 inactivation before and after murine postnatal Day 14 (P14) [4,6]. The Pkd1<sup>flox/flox</sup>;Mx1Cre<sup>+</sup> inducible model has recently been described [10] where Cre-mediated recombination is dependent upon the viral response and endogenous interferon (IFN) production in response to double stranded polyinosinic–polycytidylic acid (pl:pC) injection. As target gene inactivation using the Mx1Cre mouse has been shown to be ~50% in the kidney [11,12], it was possible that this system could be used for the development of a less aggressive (i.e. fewer affected kidney epithelial cells) ADPKD disease progression model. However, while it may be possible to modulate the extent of Mx1Cre-mediated recombination of Pkd1 by pl:pC dosing, previous studies have shown that genetic inactivation of Pkd1 before P14 caused rapid cyst progression within 3 weeks, whereas adult inactivation resulted in few focal kidney cysts after several months [10].

As Pkd1 defects are the primary cause of ADPKD, the ultimate goal would be to develop a slowly progressing Pkd1-based murine model in which to test possible therapeutic agents against cystogenesis and cyst expansion. We have previously shown that the small molecule triptolide can reduce cyst formation and cystic burden in the in utero Pkd1<sup>−/−</sup> mouse model [13] and in the aggressive neonatal Pkd1<sup>−/−</sup>;KspCre<sup>+</sup> model [14]. As triptolide can induce polycystin-2 (PC2) dependent calcium release and inhibit proliferation of Pkd1<sup>−/−</sup> cells [13], we continue to test the efficacy of this potential therapeutic in murine models of ADPKD. As compared to the previous Pkd1 models tested with triptolide (Pkd1<sup>−/−</sup> and Pkd1<sup>flox/flox</sup>;KspCre<sup>+</sup>), the Pkd1<sup>flox/flox</sup>;Mx1Cre<sup>+</sup> model has several benefits including normal kidney development until P10, a longer lifespan and a lower percentage of kidney epithelial cells with Pkd1<sup>−/−</sup> inactivation, thus making disease progression less aggressive than in the previous in utero or neonatal models. Since the Pkd1<sup>flox/flox</sup>;Mx1Cre<sup>+</sup> model had not been tested with any drug therapy regimens and cyst formation when initiated before P14 would allow for examination of cystic burden in an otherwise healthy animal after 3 weeks, we began experiments to determine if triptolide would affect cyst formation in this less aggressive Pkd1-derived ADPKD model.

The goals of this study were to establish a baseline of reproducible cyst formation and progression following P10/P12 induction of Mx1Cre-mediated excision of Pkd1, to determine what effect triptolide would have in a more slowly advancing mouse model of cystic disease and to evaluate the feasibility of using the Pkd1<sup>flox/flox</sup>,Mx1Cre<sup>+</sup> model in a long-term adult Pkd1 inactivation model for drug therapy studies.

**Materials and methods**

**Animal studies**

Mx1Cre mice were purchased from the Jackson Laboratory (Maine, USA) and Pkd1<sup>flox</sup> mice were generated as previously described [8]. All approved animal protocols were conducted in accordance with Yale Animal Resources Center and Institutional Animal Care and Use Committee regulations. Pkd1<sup>flox/flox</sup> mice were crossed with Pkd1<sup>flox/+</sup>;Mx1Cre<sup>+</sup> mice and progeny were genotyped. For short-term studies (P35 termination), all littermates were injected intraperitoneally (i.p.) using one of the following regimens: once on postnatal Day P10, once on P12 or twice on both P10 and P12 with 250 μg pl:pC (Sigma-Aldrich, MO, USA). pl:pC was delivered in either a total volume of 12.5 or 25 μl in sterile RNase-free water. Mice were injected i.p. with triptolide or dimethyl sulfoxide (DMSO) delivered in sterile PBS beginning on Day P16 until the termination of the experiment on Day P35. Injections were daily where 0.12 mg/kg triptolide was administered from P16 to P20 and then increased to 0.25 mg/kg from P21 to P35. For long-term studies, mice were induced once at Day P30 with 250 μg pl:pC in a 50 μl volume and were euthanized 5 months after induction. Mice were anaesthetized with 30% isoflurane before submandibular puncture to collect blood for blood urea nitrogen (BUN) levels or alkaline phosphatase analyses (BioAssay Systems, CA, USA).

**Tissue histology**

Kidneys or livers were fixed in 4% paraformaldehyde, embedded in paraffin and stained with haematoxylin and eosin (H&E; AML Laborato-
Images were acquired under bright-field microscopy; cyst number and cystic burden were quantitated using Image J analysis software (NIH). Ki-67 immunohistochemistry (IHC) was performed by the Yale Pathology Core Tissue Services. Multiple fields of each kidney were photographed using a 40× or 10× objective, and cysts were counted for total cell number and the percent positive Ki-67 cells. A total of 283 cysts were counted for DMSO-treated animals and 212 cysts were counted for triptolide-treated animals. Statistical analysis was completed using KaleidaGraph software where two data sets were analysed using Student’s t-test and three or more data sets were analysed by analysis of variance (ANOVA) using Bonferroni’s post hoc analysis (α = 0.05). Significance was determined as P < 0.05. All data are presented as mean ± SE.

MRI acquisition and analysis
For magnetic resonance imaging (MRI) studies, kidneys were removed and fixed in 4% paraformaldehyde before imaging. All experiments were performed on a 15-cm horizontal bore 9.4T spectrometer (Bruker, MA, USA) with custom-made radio-frequency surface coil (15mm diameter). Multi-slice axial images were acquired using a rapid acquisition with relaxation enhancement (RARE) spin-echo sequence. Imaging parameters were as follows: field of view = 13mm, image matrix = 128 × 128, in-plane resolution = 100 × 100 μm, slice thickness = 500 μm, effective echo time = 34ms and recycle time = 5s. All MRI images were viewed using home-written Matlab (Natick, MA) software where a threshold was used to suppress the paraformaldehyde signal and reveal the tissue water signal.
Development of the Pkd1fl/fl;Mx1Cre inducible model

As our ultimate goal of this study was to be able to assess cystic burden and progression as a result of a therapeutic drug treatment regimen with triptolide, we first characterized cyst formation in this inducible Pkd1 deletion model. For postnatal Day P35 termination studies, we crossed Pkd1fl/fl with Pkd1fl/+;Mx1Cre mice to generate Pkd1fl/fl;Mx1Cre cystic mice. Normal development proceeded until neonatal Day P10 at which point we tested a combination of i.p. pI:pC induction strategies to achieve systemic Pkd1 inactivation. pI:pC inductions at P10, P12 or a combination of P10/P12 injections were tested and cyst progression was examined at 5 weeks of age (P35; Figure 1). In addition, given the small size of the neonate, we examined the effect of pI:pC volume on the reproducibility of Mx1Cre induction; 250 μg was delivered i.p. in either a volume of 12.5 or 25 μl.

Results from this short-term model showed that there was high variability of cystogenesis if only one injection of pI:pC was utilized. Animals induced at P12 with a 12.5 μl volume had no reproducible kidney cyst formation by Day P35 (data not shown) and a single induction at P10 at the same volume resulted in a moderate but highly variable cystic burden that was gender independent (Figure 1B). We next tested a double pI:pC induction schedule (P10/P12) with the low 12.5 μl volume; however, results again were highly variable between animals (Figure 1B). When we increased the pI:pC volume to 25 μl, it was not only well tolerated by the neonates but also resulted in a reproducible cystic kidney phenotype present at Day P35 (Figure 1B). While we were not able to obtain consistent results to produce a mild short-term disease model of Pkd1-dependent kidney cyst formation by either single induction or low volume injection, we successfully determined the conditions necessary for robust cyst initiation in this model. It is also of note that, at Day P35, while the kidneys had many cysts of varying sizes, these mice displayed no signs of distress, decreased activity or abdominal bulging. This suggests that while there was rapid cyst formation within 3 weeks in this model, overall survival should extend past 35 days. To examine cystogenesis further in this model, we completed all subsequent experiments using dual P10/P12 induction with a 25 μl injection volume.

Cyst formation and expansion is rapid in the Pkd1fl/fl;Mx1Cre neonate

Before beginning drug studies with triptolide or DMSO vehicle control, we first wanted to establish the baseline of cystogenesis in this model. Cyst progression was therefore examined by assessing the rate of cyst growth and expansion at P16, P22 or P35. The cystic phenotype was evident by visual inspection of kidneys at both P22 and P35 as they were larger, pale and cysts were easily seen.

Results

Development of the Pkd1fl/fl;Mx1Cre-inducible model

As our ultimate goal of this study was to be able to assess cystic burden and progression as a result of a therapeutic drug treatment regimen with triptolide, we first characterized cyst formation in this inducible Pkd1 deletion model. For postnatal Day P35 termination studies, we crossed Pkd1fl/fl with Pkd1fl/+;Mx1Cre mice to generate Pkd1fl/fl;Mx1Cre cystic mice. Normal development proceeded until neonatal Day P10 at which point we tested a combination of i.p. pI:pC induction strategies to achieve systemic Pkd1 inactivation. pI:pC inductions at P10, P12 or a combination of P10/P12 injections were tested and cyst progression was examined at 5 weeks of age (P35; Figure 1). In addition, given the small size of the neonate, we examined the effect of pI:pC volume on the reproducibility of Mx1Cre induction; 250μg was delivered i.p. in either a volume of 12.5 or 25μl.

Results from this short-term model showed that there was high variability of cystogenesis if only one injection of pI:pC was utilized. Animals induced at P12 with a 12.5 μl volume had no reproducible kidney cyst formation by Day P35 (data not shown) and a single induction at P10 at the same volume resulted in a moderate but highly variable cystic burden that was gender independent (Figure 1B). We next tested a double pI:pC induction schedule (P10/P12) with the low 12.5 μl volume; however, results again were highly variable between animals (Figure 1B). When we increased the pI:pC volume to 25 μl, it was not only well tolerated by the neonates but also resulted in a reproducible cystic kidney phenotype present at Day P35 (Figure 1B). While we were not able to obtain consistent results to produce a mild short-term disease model of Pkd1-dependent kidney cyst formation by either single induction or low volume injection, we successfully determined the conditions necessary for robust cyst initiation in this model. It is also of note that, at Day P35, while the kidneys had many cysts of varying sizes, these mice displayed no signs of distress, decreased activity or abdominal bulging. This suggests that while there was rapid cyst formation within 3 weeks in this model, overall survival should extend past 35 days. To examine cystogenesis further in this model, we completed all subsequent experiments using dual P10/P12 induction with a 25 μl injection volume.

Cyst formation and expansion is rapid in the Pkd1fl/fl;Mx1Cre neonate

Before beginning drug studies with triptolide or DMSO vehicle control, we first wanted to establish the baseline of cystogenesis in this model. Cyst progression was therefore examined by assessing the rate of cyst growth and expansion at P16, P22 or P35. The cystic phenotype was evident by visual inspection of kidneys at both P22 and P35 as they were larger, pale and cysts were easily seen.
Triptolide reduces renal function. BUN values were measured from cystic mice over time on both P22 and P35 (n = 13 DMSO, n = 11 triptolide; asterisk indicates significance at P < 0.035 by Student's t-test). Baseline refers to the average BUN values of non-cystic mice treated with DMSO or triptolide taken on P22. Double dagger indicates P < 0.0001 for the increase in BUN from baseline through P35 for DMSO with DMSO or triptolide taken on P22. There was no increase in BUN from baseline through P35 (P = 0.10322) with triptolide treatment.

by light transmission (data not shown). While kidneys at Day P10 appeared normal, following dual P10/P12 induction, cyst formation was already evident at P16 by histological examination (Figure 2A). Additionally, microcysts were observed under higher magnification (data not shown). Cyst growth and expansion continued to proceed at a rapid rate as observed in both P22 and P35 kidneys (Figure 2A).

While (H&E) staining and histological examination of each kidney provided us with evidence of the formation of numerous cysts of varying sizes, we further explored the structural changes of the entire kidney using high-resolution MRI. A kidney pair from a single cystic male mouse at Day P35 scanned in 500μm axial-slice sections where many cysts were evident in each section with in-plane resolution of 100 × 100μm (Figure 2B). It appeared that there was a uniform distribution of cysts (white intense regions in lower row of Figure 2B) as they were present in both the kidney cortex and medulla. This was in contrast to a kidney pair from a non-cystic (Pkd1+/+ ) male mouse where no abnormalities were evident (Figure 2B).

In addition to kidney cysts, systemic Pkd1 deletion is also known to result in liver cyst formation derived from cholangiocytes. Upon examination of H&E-stained liver sections from P35 cystic mice, many small cysts could be easily identified (Figure 2C). While the overall cystic burden of the liver was minimal, we further wanted to assess liver function by alkaline phosphatase (ALP) activity from blood serum. As compared to wild-type (WT) mice at this age, cystic mice did not show any increase in ALP activity, therefore indicating that liver function was within normal limits. Following the establishment of cyst formation and progression in the kidney and no evidence of altered liver function to affect drug metabolism, we began a series of experiments to test whether triptolide could reduce cystogenesis in this neonatal to adult transition model of Pkd1 inactivation.

Triptolide reduces cyst formation in the P35 Pkd1flox/flox; Mx1Cre mouse

Having established the dosing and timing of pI:pC-induced Pkd1 deletion in this model, we next determined the triptolide treatment regimen. As pI:pC-induced IFN production in the mouse has been established to subside after 2 days, we wanted to permit the full immune response before introducing triptolide since triptolide is a known anti-inflammatory agent [15,16]. Therefore, triptolide was not administered until P16, or 4 days after the last pI:pC injection when small cysts were already evident (Figure 2A). We began i.p. injections with 0.12 mg/kg/day triptolide as we have previously shown this concentration to be well tolerated by neonates [14]. At weaning (P21), we increased the triptolide concentration to 0.25 mg/kg/day, which we have established as safe with no adverse side effects in adult mice (unpublished data).

All animals during the course of the study in either treatment group had normal behaviour, and up to the P35 termination date, no gross anatomical differences such as abdominal distention could be visualized. Control WT (Pkd1flox/+ or Pkd1flox/flox) mice in both treatment groups had normal kidneys with no evidence of cyst formation (Figure 3A). Mice (Pkd1flox/flox;Mx1Cre) treated with DMSO vehicle control had large cystic kidneys at P35 as previously demonstrated (Figure 3A). In contrast, mice treated with triptolide not only had reduced overall cystic burden but it was also evident that small cysts formed at the kidney cortex periphery were frequently reduced in number (Figure 3A). Statistical analysis of kidney sections [DMSO: n = 42 (21 mice), triptolide: n = 40 (20 mice)] confirmed that triptolide reduced the total number of cysts per kidney as well as the overall cystic burden (Figure 3B). This was especially encouraging as cyst formation had already begun when triptolide treatment commenced at P16 (Figure 2A). Although there was no difference in the combined average cyst size between the two treatment groups, as we have previously observed [14] (Figure 3B), we further analysed the data by calculating the frequency of cyst sizes (i.e. indication of cyst expansion) per group as well (Figure 3C). While the most pronounced triptolide-induced decrease was detected in the smallest cyst group (up to 100 pixels) and supported our findings that triptolide acts to delay cystogenesis in the Pkd1flox−/−;KspCre model [14], we also observed a significant decrease in the number of subsequent larger cysts. While it is not clear at this time if triptolide is directly affecting cyst enlargement, it is encouraging that we saw this result for the first time in a more slowly developing cyst progression model. In order to determine if triptolide could reduce proliferation of kidney epithelial cells, IHC was completed on kidney sections for the expression of the proliferation marker, Ki-67. Cysts of multiple sizes and stages of progression ranging from six cells to >200 cells were counted for both total cell number and the number of Ki-67-positive cells to determine the percent of proliferating cells per cyst. Triptolide reduced the proliferation rate independent of cyst size as determined by t-test analysis (Figure 3D). Although the largest cyst size group (>100 cells) had the lowest percentage of proliferating cells when compared to smaller...
cysts in DMSO-treated animals (17%), triptolide further reduced the proliferation rate to 6%.

No overt toxicity was detected as triptolide did not affect the total body animal weight in comparison to the respective WT or cystic DMSO control (data not shown). Additionally, although the percent kidney weight to body weight ratio tended to be lower in triptolide-treated cystic animals, this did not reach statistical significance as compared to DMSO control (Figure 3E).

Triptolide preserves renal function

While the results from kidney histology of triptolide-treated mice were encouraging, we also wanted to determine if the reduction in cyst number translated into a benefit in renal function as assessed by BUN and, therefore, analysed BUN changes from P22 to P35. Baseline BUN values were calculated from an average of WT mice at P22 from either DMSO- or triptolide-treated cystic animals where there was no difference between experimental groups (Figure 4). We did, however, observe a significant reduction in BUN levels from \( Pkd1^{\text{flox/flox};\text{Mx1Cre}} \) triptolide-treated animals as early as P22 when compared to DMSO control (DMSO \( n = 13: 41 \pm 3 \), triptolide \( n = 11: 31 \pm 3 \); \( P = 0.03202 \) by t-test) and this trend continued through to the P35 endpoint (DMSO \( n = 13: 53 \pm 4 \), triptolide \( n = 11: 37 \pm 3 \); \( P = 0.01047 \) by t-test). When the data were analysed by ANOVA to determine the relative change in BUN levels over time (i.e. baseline through P35), triptolide-treated mice showed no significant difference from baseline values (Figure 4). In contrast, there was a statistically significant increase in BUN levels over the same time course in animals treated with DMSO (\( P < 0.0001 \); Figure 4). Taken together, triptolide reduced cyst formation, cystic burden and preserved renal function in a neonatal to adult transition model where overt clinical signs of disease were not yet evident.

As we continued to test triptolide in progressively older \( Pkd1 \) animal models to more closely approximate human ADPKD disease progression, we were interested in pursuing the \( Pkd1^{\text{flox/flox};\text{Mx1Cre}} \) model for drug studies following adult (post-P14) \( Pkd1 \) inactivation. Therefore, we next completed an adult induction study, where cyst formation and expansion requires several months to become evident following \( Pkd1 \) deletion. We induced \( Pkd1^{\text{flox/flox};\text{Mx1Cre}} \) mice at P30 with a single injection of 250\( \mu \)g pI:pC and examined cyst formation after 5 months. Most mice, irrespective of gender or genotype, remained active and no visible signs of disease were evident over the course of the experiment; however, one male cystic mouse at 4 months of age had to be euthanized due to severe abdominal bulging. Upon necropsy, the liver was found to be severely cystic and there was development of ascites indicative of liver damage; however, the kidneys were normal with no cystic involvement. Upon dissection of the remainder of induced \( Pkd1^{\text{flox/flox};\text{Mx1Cre}} \) mice at 6 months of age, fluid-filled liver cysts were visible by eye and histological examination of H&E-stained liver sections confirmed extensive cyst formation and fibrosis in all animals (Figure 5). This was in contrast to livers from WT \( (Pkd1^{\text{flox/flox}}) \) mice where liver histology appeared normal (Figure 5).

While the livers from the long-term study mice confirmed that pI:pC induction was successful, there was little evidence of cyst formation in the kidney. A few focal cysts were apparent in the kidneys of induced animals; however, the majority of nephron structure and parenchyma were normal (Figure 5). We analysed BUN levels from \( Pkd1^{\text{flox/flox};\text{Mx1Cre}} \) mice and the average was 30 ± 3.2mg/dl (\( n = 5 \)), indicating that kidney function was comparable to control animals (26 ± 0.7, \( n = 2 \); \( P = 0.1244 \)).
While it is possible that we would need to extend our study to observe kidney cyst progression with this induction schedule, it is also possible that we might have to increase the number of pI:pC injections in the adult mouse to induce cysts in the kidney. However, as liver cyst formation is already severe with the current induction protocol, it is doubtful that the mice would survive to the point of kidney cyst formation as liver failure would likely lead to premature death.

**Discussion**

The *Pkd1*<sup>fl/fl</sup>;*Mx1Cre* mouse model of ADPKD has recently been described [10], although it had not yet been used to test potential therapeutic agents. In this study, we have assessed the small molecule triptolide for its ability to reduce cyst formation in this system. Although we have previously shown that triptolide is a promising candidate for ADPKD therapeutic intervention, our continued goal is to examine its efficacy in older *Pkd1*-derived murine models where cyst progression extends to adulthood. As the *Pkd1*<sup>fl/fl</sup>;*Mx1Cre* IFN-inducible mouse permits the specific timing of *Pkd1* deletion and results in rapid (but not fatal) cyst formation within 3 weeks following neonatal (pre-P14) *Pkd1* inactivation, this was an appropriate model in which to test the effect of triptolide.

Since we were testing a drug that could reduce cyst formation, we first had to confirm the reproducibility of this induction model. As the immune response to dsRNA leading to IFN production may vary between animals, we first tested the severity of kidney cystogenesis upon induction within several days of the P14 developmental window and modulation of i.p. injection volumes. Results from this short-term study demonstrate that a modest volume increase (from 12.5 to 25 μl) compounded with dual induction decreased intrinsic experimental error and allowed us to obtain reproducible kidney cyst formation and progression without an immediate and fatal decline in kidney function. By P35, at the termination of the experiment, kidney cysts were numerous and of varying size, BUN levels had increased but had not led to renal failure or any obvious physical abnormalities and cholangiocyte-derived liver cysts were present but were not severe with no evidence of altered hepatic function.

We have previously demonstrated that triptolide reduces cystic burden in embryonic *Pkd1<sup>−/−</sup>* mice [13]; however, due to fatal developmental abnormalities, triptolide administration was limited to a short in utero treatment regimen. Subsequent experiments using the neonatal *Pkd1*<sup>fl/fl</sup>;*KspCre* mouse model of ADPKD, in which cyst formation and enlargement is aggressive and mice commonly die by 2 weeks of age, established that triptolide reduces cystic burden by decreasing cyst formation but not cyst expansion. Although pre-P14 inactivation of *Pkd1* results in an accelerated cystic disease (as compared to adult induction) in this current *Pkd1*<sup>fl/fl</sup>;*Mx1Cre*-inducible model of cystogenesis, mice remain healthy and viable at >1 month of age. Therefore, with this mouse model we can assess a longer treatment regimen of triptolide and more closely approximate any benefit resulting in the inhibition of cyst formation transitioning from the neonatal period of development to adult.

We began triptolide injections 4 days (P16) after the last pl:pC injection to allow for the full effect of IFN-induced *Pkd1* inactivation, when small cysts were already evident (Figure 2A). At the termination of the experiment at Day P35, triptolide, as previously shown in more aggressive *Pkd1*-dependent ADPKD models, reduced the total number of cysts and overall cystic burden. Renal function, already showing signs of decline as assessed by increasing BUN levels on Day P22, was reduced in the presence of triptolide only 6 days after the start of injections and continued through to the P35 endpoint. Histological examination of H&E-stained kidney sections showed a significant reduction in the number of small, newly formed cysts, suggesting that triptolide attenuates cystogenesis or delays progression of cellular proliferation. When the distribution of cyst sizes per kidney was also analysed for any differences in the number per size group, we were surprised to observe an almost uniform decrease in cysts at all stages of expansion. These results may partially be explained by the reduction in cyst cell proliferation that we observed following Ki-67 staining. Triptolide treatment led to a decrease in the number of actively dividing cells in all cyst sizes that could then lead to the overall reduction in total cyst numbers. From these experiments, it is not yet clear what role triptolide is having on larger cysts that may have formed before drug administration; however, since this is the first longer-term and less aggressive model of *Pkd1*-induced cyst formation in which triptolide has been tested, it is possible that its therapeutic potential may extend beyond inhibition of the earliest stages of cyst initiation. Future studies are planned to address this as a reduction of cystic burden through attenuation of small cyst progression may directly affect pre-existing cyst expansion or further deterioration of the surrounding parenchyma. It is also possible that in a longer-term model, triptolide’s known anti-inflammatory effects may also contribute to maintaining renal integrity and function, as leukocyte infiltration into the kidney is associated with disease progression.

The use of the *Pkd1*<sup>fl/fl</sup>;*Mx1Cre* mouse model for therapeutic drug studies may be limited to pre-P14 *Pkd1* deletion and a shorter time course for the evaluation of cyst progression as adult *Pkd1* excision leads to aggressive liver cyst formation. Although liver cysts were reported in the study by Takakura et al. [10], they were not observed until almost 1 year of age following *Pkd1* inactivation at 5 weeks. Differences in the genetic background of the mice used or differences in pl:pC concentration and frequency of injections may add to the discrepancy seen between studies. Our model and pl:pC induction schedule in adult animals results in severe cystic liver disease as *Mx1Cre*-mediated excision has previously been shown to be nearly 100% in the liver [11]. It is, however, interesting that *Pkd1* inactivation in the neonate leads to a faster cyst expansion in the kidney while inactivation in the adult mouse leads to a more aggressive liver disease. This *Pkd1*<sup>fl/fl</sup>;*Mx1Cre* model may therefore be of use in dissecting the mechanisms of cyst formation in two relevant target organs in ADPKD as the development of hepatic cysts is a frequent extra-renal manifestation in humans [17].
The \textit{Pkd1}\textsuperscript{flox/flox}, \textit{Mx1Cre} mouse adds another alternative to ADPKD models that are currently available and should be amenable to future therapeutic drug studies. A long-term drug study with the use of this model would have been ideal as a slowly progressive ‘adult’ model of ADPKD would more closely mimic the human condition as \textit{Pkd1} would be subject to inactivation in every organ system; however, extensive liver cyst formation makes this problematic as drug metabolism may be altered.

Triptolide, a small molecule previously known to act as an anti-inflammatory and anti-cancer compound, has shown efficacy as a possible therapeutic for the treatment of ADPKD. It causes polycystin-2-dependent calcium release, increases p21 expression and arrests \textit{Pkd1}\textsuperscript{−/−} renal epithelial cell proliferation. Our previous in vivo studies with triptolide in the \textit{Pkd1}\textsuperscript{−/−} \textit{in utero} mouse and the neonatal \textit{Pkd1}\textsuperscript{flox/flox}, \textit{KspCre} mouse have shown that, even in these aggressive and rapidly fatal models, cystic burden and cyst numbers decreased. In our endeavour to study triptolide efficacy in \textit{Pkd1}-dependent ADPKD, we continue to test triptolide in those models that more closely approximate the human condition such as a slow progression to ESRD. In this study, using the \textit{Pkd1}\textsuperscript{flox/flox}, \textit{Mx1Cre} mouse, we have not only confirmed previous results that triptolide decreases cyst initiation but we have also observed a general decrease in the number of larger cysts as well. As murine \textit{Pkd1} models are developed that result from \textit{Pkd1} inactivation induced in \textit{Mx1Cre} cells. We have better elucidated the full therapeutic potential of triptolide as an inhibitor of cyst initiation and what impact that may have on the expansion of mature cysts, kidney inflammation and the preservation of renal function and integrity.

\textbf{Acknowledgement.} This work was supported by research grants from US National Institutes of Health (AI055914 to C.M.C.; P30, NS-052519 to F.H.).

\textbf{Conflict of interest statement.} None declared.

\textbf{References}


Received for publication: 1.6.09; Accepted in revised form: 24.12.09